Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
- Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the Company evaluates implications of PROSERA results - - The Company implemented a reduction in force to align resources with near-term priorities - - Cash, cash equivalents and marketable securities totaled $137 million at year-end 2025 - SAN DIEGO, March 17, 2026 BUSINESS WIRE )--Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement. "Following our PROSERA topline results, we are focused on fully understanding the PROSERA dataset, engaging with the FDA, and eva
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio (GOSS) had its "neutral" rating reaffirmed by Cantor Fitzgerald.MarketBeat
- Biotech company cuts half its staff after disappointing trial sees stock plummet [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSSPR Newswire
- GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial FailsGlobeNewswire
- GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial FailsPR Newswire
GOSS
Earnings
- 3/17/26 - Miss
GOSS
Sec Filings
- 3/24/26 - Form SCHEDULE
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- GOSS's page on the SEC website